Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)

NCT02662920 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT02662920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02662920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)
Lead sponsor
Wake Forest University Health Sciences
Phase
Observational
Overall status
Completed
Start date
August 31, 2010
Completion date
November 30, 2014
Enrollment
209 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia